<div id="readability-page-1"><p>01:35 PM EST, 12/29/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:</p><p>We reduce our target price to $422 from $470 based on our NPV analysis. We maintain our 2025 EPS forecast at $4.98 and our 2026 view at $9.72. We updated our model and slightly lowered our full-year 2025 revenue estimate to $3.8B from $3.9B, as we now see the TTR franchise revenue closer to $2.49B, at the lower end of the revenue guidance range of $2.475B-$2.525B shared in October. At the same time, we see the recently announced manufacturing investment as a positive decision for the long term, as it aims to increase capacity and reduce costs. In early December, ALNY announced a significant manufacturing investment worth $250M to expand its Norton, MA facility, which is expected to position ALNY as an innovation hub. By expanding its existing site, which is planned to be completed in late 2027, ALNY aims to produce both clinical and commercial supply of siRNA oligonucleotide drug substance globally. Shares of ALNY went down by more than 17% since we lowered our rating to Hold from Buy on October 29.</p> <p>MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</p></div>

阿里拉姆制藥

<p>CFRA 對阿里拉姆製藥保持持有評級，並根據淨現值分析將目標價格從 470 美元下調至 422 美元。2025 年每股收益預測仍為 4.98 美元，2025 年全年收入預估略微下調至 38 億美元。TTR 產品線的收入現預計為 24.9 億美元。最近的一項 2.5 億美元的製造投資旨在提升產能並降低成本，使阿里拉姆成為創新中心。自 10 月 29 日評級調整為持有以來，股價已下跌超過 17%</p>

研究警報：CFRA 維持對 Alnylam Pharmaceuticals, Inc.股票的持有意見